YD Bio Ltd
No enriched coverage for $YDES in the last 7 days.
No SEC Form 4 filings for $YDES in the last 30 days.
See all $YDES insider activity →After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
YD Bio Limited (Nasdaq: YDES) said its affiliate EG BioMed US obtained out-of-state CLIA/CAP laboratory licenses in Rhode Island (clinical genetics, issued May 13, 2026) and Pennsylvania (clinical chemistry/hematology, issued June 9, 2026). The Bothell, Washington lab’s footprint now covers 46 states plus DC and Guam, supporting blood-based early cancer detection testing via its telehealth platform.
Recent YDES coverage spans financial news, market movers and regulation.
Revenue growth with worsening losses can sustain speculative interest while keeping downside risk elevated.
Speculative interest may be driven by FDA-pathway progress and potential Breakthrough Device designation discussion.
New state licensing expands the company’s regulated diagnostic footprint, supporting broader patient access and faster accumulation of real-world molecular data.
The launch of YD Bio's telehealth platform signifies strategic expansion into cancer diagnostics, potentially enhancing its market position and revenue streams.
The filing of a Form 3 by YD Bio's director indicating no insider transactions suggests stability in insider ownership and no immediate insider trading activity. This neutrality implies no current insider-driven trading signals for YDES.
alphai scores every news story that mentions YDES with an AI model for sentiment and relevance, and aggregates insider trades from YD Bio Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
7 min readBiotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min readYD Bio Limited (Nasdaq: YDES) said its affiliate EG BioMed US obtained out-of-state CLIA/CAP laboratory licenses in Rhode Island (clinical genetics, issued May 13, 2026) and Pennsylvania (clinical chemistry/hematology, issued June 9, 2026). The Bothell, Washington lab’s footprint now covers 46 states plus DC and Guam, supporting blood-based early cancer detection testing via its telehealth platform.
3 min readYD Bio Limited has announced the launch of its EG Telehealth Platform in collaboration with EG BioMed Co., Ltd., expanding cancer detection and monitoring services across 44 U.S. states, Washington, D.C., and Guam. This platform combines YD Bio's digital health infrastructure with EG BioMed's laboratory capabilities to screen for various cancers, including pancreatic, colorectal, liver, gastrointestinal, and breast cancers. The launch is a step towards scalable deployment, coinciding with YD Bio's ongoing plans to merge with EG BioMed and recent acquisitions to enhance its technological capabilities.
4 min readYD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES, indicating no reported purchases, sales, or other insider transactions. The filing lists him as a director, with all transaction counts and share totals recorded as zero. This Form 3 filing confirms no insider trading activity from the specified director.
1 min readTaipei, Taiwan, Oct. 10, 2025 ( GLOBE NEWSWIRE ) -- YD Bio Limited ( "YD Bio" or the "Company" ) ( Nasdaq: YDES ) , a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that its business partner, EG Biomed US Inc. ( ...
3 min read
